TAF9

Across TCGA pan-cancer cohorts, TAF9 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TAF9 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher TAF9 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TAF9 expression acts as an unfavorable survival marker, although some lineages such as UCEC and PDAC show a favorable association.

UCEC, LUAD, and PDAC are the cancer types where TAF9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Quartile	III,IV	1.000	0.253	.016	28	view →
LUAD	OS	Median	II,III,IV	0.336	0.875	<.001	11	view →
PDAC	DFS	Tertile	All	0.677	0.279	.028	6	view →
HNSC	DFS	Tertile	All	1.000	0.915	.048	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TAF9–UCEC (OS)

Open the UCEC breakdown →